Core Viewpoint - Onconetix, Inc. has announced a licensing agreement with Immunovia AB for the production of antibodies related to pancreatic cancer diagnostics, which is expected to enhance the early detection of pancreatic cancer through the PancreaSure test [1][2]. Group 1: Licensing Agreement Details - Proteomedix AG, a subsidiary of Onconetix, will provide Immunovia with master cells necessary for producing antibodies for three of the five biomarkers in the PancreaSure test [2]. - The agreement includes a license for key intellectual property related to the manufacturing of reagents for measuring these biomarkers, allowing Immunovia to purchase reagents directly from Proteomedix [2]. - Immunovia will pay a total of $700,000 to Proteomedix in 2025 and 2026, along with a 3% royalty on net sales of PancreaSure and other products using the licensed intellectual property from 2026 to 2032 [3]. Group 2: Company Focus and Products - Onconetix is focused on innovative solutions for men's health and oncology, with a particular emphasis on the early detection of prostate cancer through its Proclarix® test [4][5]. - Proclarix® is CE-certified and indicated for prostate cancer diagnosis in patients with specific clinical conditions, demonstrating reliability in detecting clinically significant prostate cancer [6].

Core Viewpoint - OPKO Health, Inc. is set to report its operating and financial results for the second quarter and first half of 2025 on July 31, 2025, after U.S. market close [1] Group 1: Financial Reporting - The financial results will cover the three and six months ended June 30, 2025 [1] - A conference call and live audio webcast will be held on July 31 at 4:30 p.m. Eastern time to discuss the results and provide financial guidance [1] Group 2: Conference Call Information - Participants are encouraged to pre-register for the conference call to receive a unique PIN for immediate access [2] - Those unable to pre-register can join by dialing specific numbers for U.S. and international participants [2] Group 3: Replay Information - A telephone replay of the conference call will be available until August 7, 2025, with specific dialing instructions provided [3] - A webcast replay will be accessible approximately one hour after the live call [3] Group 4: Company Overview - OPKO Health is a multinational biopharmaceutical and diagnostics company focused on establishing leading positions in rapidly growing markets through its expertise and proprietary technologies [4]